A phase III study of the effect of rosuvastatin on left ventricular remodeling and inflammatory markers in heart failure
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2014
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Cardiomyopathies; Heart failure
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 24 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Aug 2008 Planned end date added (1 Dec 2009) as reported by ClinicalTrials.gov.